Several reasons why NHPs Matter in Preclinical Drug Development
- High target cross-reactivity enables precise, human-relevant R&D.
- Proved human biomarker expression in healthy and disease models in NHP
- Clinical diagnostic and interventional procedures ensuring smooth translation
Several reasons why Prisys stood out in this field:
- Unstopped R&D efforts and investments to advance NHP technologies
- 10,000+ NHPs in colony enabling flexible animal screening and study design
- Integrated resources reduce cost, lead times, and availability challenges.
Key R&D Milestones in Q1-Q2, 2025
-
Atopic Dermatitis 🔹Strengthened Immunology & Inflammation Portfolio
- Translational NHP models of 'Atopic March': Atopic Dermatitis, Asthma…
- AI-based NHP 'scratch-counts' for the evaluation of anti-pruritic treatments
- Imaging-based translational diagnosis in NHP models: IBD, pneumonia etc.
- Reliable immunotoxicity Models (TDAR) to track changes in immunocytes
-
Putamen CED infusion in Cyno 🔹Industrial-scale CNS Models with Innovative Solutions
- Translatable iMRI brain delivery at industrial-scale and standards
- Expanded BBB-bypass strategies: ICV, Brain-parenchymal, IT, N2B…
- Automated NHP behavioral trajectory for Neuro-/Mental- Safety
- NHP models of pain: acute & chronic, inflammatory & neuropathic
-
Cyno brain activation detected by BOLD fMRI 🔹Expanded Capabilities in CVRMD Research & NHP Models
- NHP Model of 'High- Fructose-Corn-Syrup' for human disease simulation
- Disease progression: from acute to chronic, from inflammation to fibrosis
- State-of-the-art clinical imaging: MR/CT/US-based diagnosis
- Spontaneous disease within NHP colonies: metabolic, aging, gynecology
Core R&D Projects in Q3-Q4: Open for 'Co-develop'
- NHP Model of Chemotherapy induced neuropathy and pain assessment
- NHP Models of Neurodegeneration : Parkinson's (α-syn), Alzheimer's (Aβ)
- Refining NHP Models of Autoimmunity: SLE, IgAN, IPF, MS, etc.
Let's bridge the translational gap together!
Prisys Biotechnologies is an AAALAC-accredited preclinical CRO in Shanghai, specializing in translational NHP models. We use advanced technology and offer over 40 NHP disease models (neuroscience, immunology, metabolism) to accelerate therapeutic innovation.
